H1N1 ¹é½Å ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø : Åõ¿© °æ·Îº°, ºê·£µå À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Type of Brand, By Distribution Channel, By Region & Competition, 2020-2030F
»óǰÄÚµå : 1691804
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 186 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

H1N1 ¹é½Å ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 99¾ï 1,000¸¸ ´Þ·¯·Î 2030³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 4.23%ÀÇ CAGRÀ» ±â·ÏÇÏ¸ç °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

H1N1 ¹é½Å ¼¼°è ½ÃÀåÀº ÁÖ·Î H1N1 ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÀÇ ¿¹¹æ ¹× È®»ê ¾ïÁ¦¿¡ ÃÊÁ¡À» ¸ÂÃá ÇコÄÉ¾î »ê¾÷ÀÇ Áß¿äÇÑ ±¸¼º¿ä¼Ò·Î, ÀϹÝÀûÀ¸·Î µÅÁö ÀÎÇ÷翣ÀÚ·Î ¾Ë·ÁÁø H1N1 ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÀÇ ¿¹¹æ ¹× È®»ê ¾ïÁ¦¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. H1N1 ¹é½Å ¼¼°è ½ÃÀåÀº µ¶°¨ À¯ÇàÀÇ Áõ°¡¿Í ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀº °èÀý¼º µ¶°¨ ¹× À¯Ç༺ µ¶°¨À» ¿¹¹æÇϱâ À§ÇØ ¿¹¹æÁ¢Á¾¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ÀÌ´Â H1N1 ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÅÁ¾ ÀÎÇ÷翣ÀÚ °¨¿°À¸·Î ÀÎÇØ ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇϱ⠽¬¿î ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù¿¡ ¹ßÇ¥µÈ CDCÀÇ ÃßÁ¤¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¾à 10¾ï °ÇÀÇ °èÀý¼º µ¶°¨ »ç·Ê°¡ ¹ß»ýÇßÀ¸¸ç, ±× Áß ¾à 300¸¸-500¸¸ °ÇÀÌ ÁßÁõÀ¸·Î ºÐ·ùµË´Ï´Ù. °¨½Ã °­È­, À¯Åë, °ø±Þ ¹× Åõ¿© ¸ð´ÏÅ͸µ¿¡ ÁßÁ¡À» µÐ ±¹°¡ ¹× ¼¼°è Â÷¿ø¿¡¼­ ¹é½Å Á¢Á¾¿¡ ´ëÇÑ Á¤ºÎÀÇ °­·ÂÇÑ Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 99¾ï 1,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 126¾ï ´Þ·¯
CAGR : 2025-2030³â 4.23%
±Þ¼ºÀå ºÎ¹® ¿Â¶óÀÎ ¾à±¹
ÃÖ´ë ½ÃÀå ºÏ¹Ì

ÀçÁ¶ÇÕ ¹é½Å°ú º¸Á¶ ¹é½ÅÀ» Æ÷ÇÔÇÑ ¹é½Å °³¹ßÀÇ ¹ßÀüÀ¸·Î ¹é½Å È¿´ÉÀÌ Çâ»óµÇ°í º¸±ÞÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ½ÅÁ¾ H1N1 ¹ÙÀÌ·¯½º ±ÕÁÖÀÇ ÃâÇöÀ¸·Î ¹é½ÅÀÇ Áö¼ÓÀûÀÎ ¾÷µ¥ÀÌÆ®°¡ ÇÊ¿äÇÏ°Ô µÇ¾î ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Ȱ¹ßÇÑ ¿¬±¸°³¹ß Ȱµ¿, WHO ¹× CDC µî ¼¼°èº¸°Ç±â±¸ÀÇ ÀÚ±Ý Áö¿ø, Á¦¾à±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ´Â ¹é½ÅÀÇ ½Å¼ÓÇÑ °³¹ß ¹× À¯Åë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, COVID-19ÀÇ ´ëÀ¯ÇàÀ¸·Î È£Èí±â °¨¿°¿¡ ´ëÇÑ ±¹¹ÎµéÀÇ ÀνÄÀÌ ³ô¾ÆÁ® ¹é½Å ÀÎÇÁ¶ó°¡ °­È­µÇ¾ú½À´Ï´Ù. Á¤ºÎÀÇ °íÀ§Ç豺¿¡ ´ëÇÑ µ¶°¨ ¹é½Å Á¢Á¾ Àǹ«È­ È®´ë¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ±â¹Ý ¹× mRNA Ç÷§ÆûÀ» Æ÷ÇÔÇÑ ¹é½Å Á¦Á¶ÀÇ ±â¼ú ¹ßÀüÀº È¿À²¼º°ú È®À强À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. µû¶ó¼­ º¸´Ù ±¤¹üÀ§ÇÑ µ¶°¨ ¿¹¹æ È¿°ú¸¦ Á¦°øÇϴ ȥÇÕ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ±â¼ú Çõ½Å°ú ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ

ÆÒµ¥¹Í ´ëºñ ¹× ÀÎ½Ä Á¦°í

ÁÖ¿ä ½ÃÀå °úÁ¦

¹ÙÀÌ·¯½ºÀÇ º¯ÀÌ¿Í ÁøÈ­

ÁÖ¿ä ½ÃÀå µ¿Çâ

¹ü¿ë µ¶°¨ ¹é½Å

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ H1N1 ¹é½Å ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå Á¶»ç ȸ»ç ¼Ò°³ ¹× ¸éÃ¥»çÇ×

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global H1N1 Vaccines Market was valued at USD 9.91 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2030. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu. The global H1N1 vaccines market is driven by multiple factors, primarily the rising prevalence of influenza outbreaks and the increasing awareness of vaccination programs. Governments and healthcare organizations worldwide are investing in immunization initiatives to prevent seasonal and pandemic influenza, fueling demand for H1N1 vaccines. The growing elderly population, which is more susceptible to severe complications from H1N1 infections, further boosts market growth. For instance, according to CDC estimates published in October 2023, nearly one billion cases of seasonal influenza occur worldwide, with approximately 3-5 million classified as severe. The increased surveillance efforts and strong government support for vaccination at both national and global levels-focusing on monitoring distribution, supply, and administration-are key factors driving market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 9.91 Billion
Market Size 2030USD 12.60 Billion
CAGR 2025-20304.23%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Advancements in vaccine development, including recombinant and adjuvanted vaccines, enhance efficacy and drive adoption. The emergence of new H1N1 virus strains necessitates continuous vaccine updates, supporting market expansion. Increasing R&D activities, funding from global health organizations such as the WHO and CDC, and strategic collaborations among pharmaceutical companies contribute to the rapid development and distribution of vaccines. The COVID-19 pandemic has heightened public awareness of respiratory infections, strengthening the overall vaccine infrastructure. Expanding government mandates for influenza vaccination in high-risk groups, coupled with favorable reimbursement policies, further stimulate market growth. Technological advancements in vaccine production, including cell-based and mRNA platforms, offer improved efficiency and scalability. Therefore, the rising demand for combination vaccines that provide broader influenza protection is expected to drive innovation and market expansion in the coming years.

Key Market Drivers

Pandemic Preparedness and Awareness

Pandemic preparedness and awareness play a crucial role in driving the growth of the global H1N1 vaccines market. Governments, health organizations, and pharmaceutical companies have intensified efforts to strengthen pandemic response strategies, ensuring rapid vaccine development, stockpiling, and distribution. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to promote global surveillance programs, early detection systems, and public awareness campaigns, increasing the demand for H1N1 vaccines. The COVID-19 pandemic has further underscored the importance of robust vaccination programs, leading to improved healthcare infrastructure and vaccine supply chains. Growing public awareness about the risks of influenza pandemics has encouraged higher vaccination rates, particularly among vulnerable populations such as the elderly, pregnant women, and immunocompromised individuals. Governments worldwide are implementing mandatory vaccination policies for healthcare workers and high-risk groups, boosting market expansion. The pandemic preparedness initiatives have led to significant investments in vaccine research, resulting in the development of more effective and rapidly deployable H1N1 vaccines, including cell-based and mRNA-based formulations. Increased collaboration between public and private sectors has accelerated vaccine accessibility, further driving market growth. As global preparedness measures continue to evolve, the demand for H1N1 vaccines is expected to rise, ensuring better pandemic resilience. According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory-related deaths annually. In industrialized countries, the majority of influenza-related deaths occur in individuals over 65 years old. Seasonal influenza can lead to a wide range of health outcomes, from mild illness to severe complications and even death.

Key Market Challenges

Virus Mutations and Evolution

Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production, driving the need for advanced manufacturing technologies and robust global monitoring systems. Governments and health organizations, such as the WHO and CDC, play a crucial role in identifying dominant strains and recommending vaccine updates, ensuring continued market demand. The pharmaceutical companies invest heavily in innovative vaccine platforms, such as mRNA and cell-based technologies, to enable faster production and adaptability to viral mutations. The unpredictable nature of influenza outbreaks necessitates strategic vaccine stockpiling and rapid distribution systems, further fueling market growth. As global health preparedness efforts intensify, the demand for adaptable and effective H1N1 vaccines continues to rise, supporting the expansion of the market.

Key Market Trends

Universal Influenza Vaccines

One of the most promising trends driving the growth of the global H1N1 vaccines market is the development of universal influenza vaccines. Unlike traditional seasonal flu vaccines, which require frequent updates to match circulating strains, universal vaccines aim to provide long-lasting immunity against multiple influenza subtypes, including H1N1. These vaccines target conserved regions of the virus, such as hemagglutinin stalk domains and internal viral proteins, which undergo fewer mutations compared to surface antigens. By inducing broader immune responses, universal vaccines could significantly reduce the burden of annual vaccinations and enhance pandemic preparedness. Pharmaceutical companies and research institutions are actively investing in advanced vaccine platforms, including mRNA, viral vector, and nanoparticle-based approaches, to accelerate universal vaccine development. The growing support from governments and global health organizations is further driving clinical trials and regulatory approvals. A successful universal influenza vaccine could streamline vaccine manufacturing, reducing production costs and distribution challenges. This breakthrough would be particularly beneficial for low- and middle-income countries with limited healthcare resources, improving global access to influenza prevention. As research progresses and technological advancements continue, universal influenza vaccines have the potential to transform the H1N1 vaccines market, offering a more efficient and sustainable approach to combating influenza outbreaks worldwide.

Key Market Players

Report Scope:

In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

H1N1 Vaccines Market, By Route of Administration:

H1N1 Vaccines Market, By Type of Brand:

H1N1 Vaccines Market, By Distribution Channel:

H1N1 Vaccines Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.

Available Customizations:

Global H1N1 Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global H1N1 Vaccines Market Outlook

6. North America H1N1 Vaccines Market Outlook

7. Europe H1N1 Vaccines Market Outlook

8. Asia-Pacific H1N1 Vaccines Market Outlook

9. South America H1N1 Vaccines Market Outlook

10. Middle East and Africa H1N1 Vaccines Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

. 14.1.1. Business Overview

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â